Acrivon Therapeutics, Inc. Common Stock

NASDAQ:ACRV

Biotechnology

Healthcare
$1.56 +3.16%

+$0.05 today

Market cap
$66.94M
Beta
1.91
P/E (TTM)
-0.8
EPS (TTM)
-$2.00
52W Low $1.15High $3.56

Volume 0.61M

Average 0.60M

ACRV Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Acrivon Therapeutics, Inc. Common StockNASDAQ: ACRV

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $383K rose 23.2% year over year, ahead of the +8.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 6.1% from the prior quarter. Over 3 fiscal years it compounded at +36.2% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +23.2% holds above the trailing-twelve-month pace of +8.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$383K+6.1% QoQ
Last fiscal yearDec 2025
$919K-8.6% YoY
LTMMar 2026
$1.21M+8.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.2%——
1 year-8.6%——
3-year CAGR+36.2%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
919K USD
Year-over-year change
-8.6%
4-year CAGR
+123.2%

Depreciation & Amortization vs competitors

How ACRV compares with its peers on the latest reported figures

  • ACRV's LTM Mar 2026 depreciation & amortization of $1.21M is the 5th largest of the 10 companies compared; the peer median is $960K.
  • Its year-over-year change of +8.3% is the 3rd highest of 9, against a peer median of -15.7%.
  • Over three fiscal years its annual growth of +36.2% compares with a peer median of +20.4%.
ACRV Competitors Peer median
Depreciation & Amortization for ACRV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VXRTVaxart, Inc.LTM Mar 2026$7.74M -13.3%+13.9%3.0%
CBUSCibus, Inc.LTM Mar 2026$5.46M -18.2%+56.9%127.4%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$2.88M -18.4%-17.7%31.5%
ATYRaTyr Pharma, Inc.LTM Mar 2026$1.56M +35.6%-2.9%823.2%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$1.21M +8.3%+36.2%—
BMEABiomea Fusion, Inc.LTM Mar 2026$960K -46.5%+26.8%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$648K +132.3%+52.6%—
IMUXImmunic, Inc.LTM Mar 2026$158K +4.6%+29.7%—
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$131K -84.0%-41.1%—
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 ———
Peer median (excluding ACRV) $960K-15.7%+20.4%79.5%

Competitors are the stored peer set for ACRV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(16.24M)(31.17M)(60.39M)(80.56M)(77.91M)
Depreciation & Amortization37K364K536K1.01M919K
Deferred Income Tax00(3.61M)00
Stock-Based Compensation497K2.19M11.62M14.29M14.72M
Change in Working Capital328K(1.53M)8.14M2.44M(2.43M)
Accounts Receivables00000
Inventory00000
Accounts Payables798K(245K)3.61M(3.59M)1.54M
Other Working Capital(470K)(1.29M)4.53M6.02M(3.96M)
Other Non-Cash Items1.4M33K1.06M(2.85M)1.03M
Operating Cash Flow(13.98M)(30.12M)(42.64M)(65.67M)(63.67M)
Capital Expenditures(238K)(2.17M)(1.29M)(2.77M)(1.67M)
Acquisitions (Net)00000
Purchases of Investments0(150.18M)(56.53M)(202.93M)(81.73M)
Sales of Investments010.67M108.53M153.92M149.5M
Other Investing Activities00000
Investing Cash Flow(238K)(141.68M)50.72M(51.77M)66.1M
Debt Repayment00000
Common Stock Issued0104.46M(257K)70M1K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1K(2.75M)(1.3M)51.03M(750K)
Financing Cash Flow112.22M101.71M(1.55M)121.03M(749K)
Effect of Forex Changes00000
Net Change in Cash98M(70.08M)6.52M3.59M1.69M
Free Cash Flow(14.22M)(32.28M)(43.93M)(68.44M)(65.33M)

Acrivon Therapeutics, Inc. Common Stock

NASDAQ:ACRV

Intrinsic Alpha fair value

Locked

Current Price

$1.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.